Access cutting-edge genetic predisposition treatment through this clinical trial at a research site in St Louis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this St Louis location
Preparing your pre-screening questions…
Access genetic predisposition specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related genetic predisposition treatment provided free
Check if you qualify for this genetic predisposition clinical trial in St Louis, MO
No-Cost Study Care
Local to St Louis
Convenient for MO residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not race - account for increased risk. For APOL1 genetic testing to be applied in a manner that improves patient care and outcomes, more information is needed regarding associations of genotype with clinical parameters related to kidney health. Further, understanding patient perceptions about knowledge of the results of APOL1 genetic testing, and how that impacts patient engagement with management of hypertension and other renal risk factors, is urgently needed. * In a Phase 1 pilot study, we offered APOL1 genetic testing to Black patients seen in our Hypertension and Nephrology clinics at Saint Louis University, an academic medical center that serves the local urban community, and surveyed patients on attitudes and concerns about APOL1 genetic testing. 144 participants were enrolled in Phase 1. * In the Phase 2 study, we will advance this important work in our community by offering participation to a broader patient base, including patients seen in Internal and Family Medicine clinics, SLU Hospital, as well as to first-degree relatives and spouses of SLUCare participants. This expansion seeks to advance understanding of environment-gene interactions, improve risk prediction, and target management of potentially modifiable risk factors.
Sponsor: St. Louis University
Yes, this clinical trial (NCT05656261) has an active research site in St Louis, MO that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for genetic predisposition treatment options in St Louis, MO, this clinical trial (NCT05656261) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our St Louis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced genetic predisposition specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all genetic predisposition clinical trials near you to find additional studies recruiting in your area.
See all neuroendocrine tumors clinical trials recruiting in St Louis — not just this study.
Browse Neuroendocrine Tumors Trials in St Louis →